Albert Knouse, MD
Family Medicine · Newport, PANPI 1871553842
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 423 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 13.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,660 and has fallen 99.0% since, to $16 in 2025. Among family medicine clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 423 payments — averaging $14.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$787
- GSK$676
- Pfizer$507
- Boehringer Ingelheim$503
- AstraZeneca$448
- AbbVie$398
- plus $3K from 29 others
Across 22 payments — averaging $43,486 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$530K
- Eli Lilly$415K
- Sanofi US Services Inc.$12K
What the payments were for
- Food & beverage$5,999100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 61 | $787 |
| GSK | 65 | $676 |
| Pfizer | 52 | $507 |
| Boehringer Ingelheim | 34 | $503 |
| AstraZeneca(2 entities) | 26 | $448 |
| AbbVie(2 entities) | 20 | $398 |
| Amgen | 21 | $388 |
| Lilly USA, LLC | 27 | $301 |
| Merck | 17 | $275 |
| Novartis | 14 | $224 |
| Johnson & Johnson(2 entities) | 13 | $222 |
| E.r. Squibb & Sons, L.L.C. | 9 | $174 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $137 |
| Sanofi Pasteur Inc. | 5 | $129 |
| Amarin Pharma, Inc. | 6 | $106 |
| Sanofi-aventis U.S. LLC | 7 | $101 |
| Biohaven Pharmaceuticals, Inc. | 5 | $86 |
| Astellas Pharma US Inc | 4 | $80 |
| Abbott | 3 | $64 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $52 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $48 |
| Grifols USA, LLC | 3 | $38 |
| Xeris Pharmaceuticals, Inc. | 2 | $34 |
| Teva Pharmaceuticals USA, Inc. | 2 | $27 |
| Genentech USA, Inc. | 2 | $26 |
| Kowa Pharmaceuticals America, Inc. | 2 | $26 |
| Organogenesis Inc. | 1 | $22 |
| Exact Sciences | 1 | $21 |
| Phathom Pharmaceuticals, Inc. | 1 | $19 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Shire North American Group Inc | 1 | $16 |
| Circassia Inc. | 1 | $15 |
| IBSA Pharma Inc. | 1 | $15 |
| Corium, LLC | 1 | $14 |
| Cequr Corporation | 1 | $14 |
How this compares
$6,013 in reported general payments places this provider in the 90th percentile of 4,967 family medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 128 | $116,786 |
| TrulicityDulaglutide | 50 | $80,224 |
| JardianceEmpagliflozin | 64 | $76,484 |
| JanuviaSitagliptin Phosphate | 65 | $54,426 |
| XareltoRivaroxaban | 36 | $41,487 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 45 | $36,243 |
| OzempicSemaglutide | 26 | $32,823 |
| MounjaroTirzepatide | 24 | $30,225 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 23 | $21,430 |
| FarxigaDapagliflozin Propanediol | 12 | $18,987 |
| Tresiba Flextouch U-100Insulin Degludec | 19 | $14,647 |
| TradjentaLinagliptin | 17 | $11,845 |
| VascepaIcosapent Ethyl | 18 | $11,708 |
| PremarinEstrogens, Conjugated | 23 | $11,211 |
| Atorvastatin Calcium | 659 | $10,022 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Premarin | $507 | $127,997151 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $301 | $110,44974 claims |
| Boehringer IngelheimJardiance, Tradjenta | $503 | $88,32981 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $676 | $57,67368 claims |
| MerckJanuvia | $275 | $54,42665 claims |
| Johnson & JohnsonXarelto | $222 | $41,48736 claims |
| Novo NordiskOzempic | $787 | $32,82326 claims |
| AstraZenecaFarxiga | $448 | $18,98712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,967 family medicine providers in Pennsylvania.
Other family medicine in Newport
- Neil SkolnikJenkintown$904K
- Lisa EspinozaNew Hope$722K
- Christopher Varacallodu Bois$627K
- Paul DoghramjiCollegeville$617K
- Brian DeyarminBethel Park$491K
- Nathan BennettPittsburgh$465K
- Gary OwensGlen Mills$404K
- Mary ZakutneyIrwin$393K
- H WilkinsSellersville$380K
- Deborah WittPhiladelphia$226K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.